Imricor Medical Systems Inc
ASX:IMR
Intrinsic Value
Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablat... [ Read More ]
The intrinsic value of one
IMR
stock under the Base Case scenario is
0.501
AUD.
Compared to the current market price of 0.485 AUD,
Imricor Medical Systems Inc
is
Undervalued by 3%.
IMR's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
IMR or that its price is influenced by factors unrelated to fundamentals.
Imricor Medical Systems Inc's market capitalization is 81.9m AUD.
IMR stock price is 0.485 AUD.
IMR stock price (0.485 AUD) is 3% less than its Intrinsic Value (0.501 AUD).
IMR. Open DCF Valuation
IMR has upside potential of 90% compared to the average analyst price target.
Open Wall St Estimates
IMR's Revenue has been falling by 4% per year for the last 3 years.
IMR's short-term liabilties (5m USD) exceed its short-term assets (4m USD).
IMR's Revenue has dropped by 25% over the past 12 months.
IMR's ROE (Return on Equity) has significantly increased in the last 3 years from -69% to 3 641%.
IMR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -186% to -257%, and is approaching profitability.
IMR has negative Operating Income for the last twelve months.
IMR has negative Net Income for the last twelve months.
IMR's ROE (Return on Equity) for the past 12 months is very high and is equal to 3 641%.
IMR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -257%.
IMR's long-term liabilties (17m USD) exceed its long-term assets (8m USD).
IMR has negative Gross Profit for the last twelve months.
IMR's Revenue is forecast to grow at a rate of 206% per year over the next 3 years.
IMR has negative Free Cash Flow for the last twelve months.
IMR has positive Net Debt. This means that the company has more debt (8m USD) than cash and short-term investments (832k USD).
IMR has very high three-year average ROE (Return on Equity): 412%. The company is very efficient at transforming stockholders' equity into net income.
IMR has negative three-year average ROIC (Return on Invested Capital): -236%. The company is not efficient at using invested capital to generate operating income.
IMR's D/E (Debt to Equity) is very low and is equal to -0.97.
IMR's Altman Z-Score is very low and is equal to -22.42.
IMR doesn't generate enough operating income (-17m USD) to safely cover interest payments on its debt (45k USD).
Valuation Backtest
Imricor Medical Systems Inc
Run backtest to discover the historical profit from buying and selling
IMR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Imricor Medical Systems Inc
Balance Sheet Decomposition
Imricor Medical Systems Inc
| Current Assets | 3.9m |
| Cash & Short-Term Investments | 831.5k |
| Receivables | 392.6k |
| Other Current Assets | 2.7m |
| Non-Current Assets | 4.4m |
| PP&E | 3.2m |
| Other Non-Current Assets | 1.2m |
| Current Liabilities | 4.6m |
| Accounts Payable | 2.1m |
| Accrued Liabilities | 1m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 12.5m |
| Long-Term Debt | 8.5m |
| Other Non-Current Liabilities | 4m |
Earnings Waterfall
Imricor Medical Systems Inc
|
Revenue
|
615.6k
USD
|
|
Cost of Revenue
|
-1.7m
USD
|
|
Gross Profit
|
-1.1m
USD
|
|
Operating Expenses
|
-15.7m
USD
|
|
Operating Income
|
-16.9m
USD
|
|
Other Expenses
|
-5.8m
USD
|
|
Net Income
|
-22.6m
USD
|
Free Cash Flow Analysis
Imricor Medical Systems Inc
| USD | |
| Free Cash Flow | USD |
IMR Profitability Score
Profitability Due Diligence
Imricor Medical Systems Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Imricor Medical Systems Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
IMR Solvency Score
Solvency Due Diligence
Imricor Medical Systems Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Score
Imricor Medical Systems Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMR Price Targets Summary
Imricor Medical Systems Inc
According to Wall Street analysts, the average 1-year price target for
IMR
is 0.919 AUD
with a low forecast of 0.851 AUD and a high forecast of 1.008 AUD.
Shareholder Return
IMR Price
Imricor Medical Systems Inc
| Average Annual Return | -5.26% |
| Standard Deviation of Annual Returns | 74.72% |
| Max Drawdown | -96% |
| Market Capitalization | 81.9m AUD |
| Shares Outstanding | 168 918 134 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Imricor Medical Systems Inc
Country
Industry
Market Cap
Dividend Yield
Description
Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The company is headquartered in Burnsville, Minnesota. The company went IPO on 2019-08-30. The firm is engaged in designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Its products include Vision-mitral regurgitation (MR) Ablation Catheter, Advantage-MR electrophysiology (EP) Recorder/Stimulator and Vision-MR Dispersive Electrode. The Vision-MR Ablation Catheter is designed to work under real-time MRI guidance. Advantage-MR EP Recorder/Stimulator System provides technology that allows physicians to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The firm sells its products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.
Contact
IPO
Employees
Officers
The intrinsic value of one
IMR
stock under the Base Case scenario is
0.501
AUD.
Compared to the current market price of 0.485 AUD,
Imricor Medical Systems Inc
is
Undervalued by 3%.
You don't have any saved screeners yet
